Submit your email to push it up the queue
Laboratorio Franco Colombiano Lafrancol S.A.S., commonly known as Lafrancol, is a prominent pharmaceutical company headquartered in Colombia. Established in 1970, Lafrancol has made significant strides in the healthcare sector, focusing on the development, manufacturing, and marketing of high-quality pharmaceutical products. The company operates primarily in Colombia and has expanded its reach across various Latin American markets. Lafrancol is renowned for its diverse portfolio, which includes prescription medications, over-the-counter products, and specialised formulations. What sets Lafrancol apart is its commitment to innovation and quality, ensuring that its products meet rigorous international standards. With a strong market position, Lafrancol has achieved notable milestones, including certifications from leading health authorities, solidifying its reputation as a trusted name in the pharmaceutical industry.
How does Laboratorio Franco Colombiano Lafrancol S.A.S.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Laboratorio Franco Colombiano Lafrancol S.A.S.'s score of 59 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Laboratorio Franco Colombiano Lafrancol S.A.S., headquartered in Colombia, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Abbott Laboratories, which cascades its climate commitments and performance metrics down to Lafrancol. While Lafrancol has not set its own reduction targets, it aligns with the sustainability initiatives of Abbott Laboratories, which is actively engaged in various climate pledges and reduction strategies. These initiatives include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions and enhancing transparency in climate-related performance. As a subsidiary, Lafrancol benefits from the overarching climate strategies of Abbott Laboratories, which may include ambitious targets for emissions reductions and sustainability practices. However, specific details regarding these targets or achievements at the subsidiary level remain unspecified. In summary, while Laboratorio Franco Colombiano Lafrancol S.A.S. does not currently report its own emissions data or reduction targets, it is positioned within a corporate framework that prioritises climate action through the initiatives of its parent company, Abbott Laboratories.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laboratorio Franco Colombiano Lafrancol S.A.S. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.